Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases
Trial ID or NCT#
NCT00928226
Status
NOT RECRUITING
Purpose
The maximum tolerated dose of 3-session (ie, treatment) stereotactic radiosurgery (SRS) to treat brain metastases greater than 4.2 cm³ in size will be determined. This study investigates if increasing radiation dose improves outcome for patients without greater toxicity (side effects).
Official Title
A Phase I/II Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Scott G. Soltys, MD
Radiation oncologist
Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery
Gordon Li, MD
Neurosurgeon
Professor of Neurosurgery and, by courtesy, of Neurology and of Otolaryngology - Head & Neck Surgery (OHNS)
Steven D. Chang, MD
Neurosurgeon,
Aneurysm neurosurgeon,
Cerebrovascular neurosurgeon,
Pituitary tumors neurosurgeon,
Stereotactic neurosurgeon
Robert C. and Jeannette Powell Neurosciences Professor and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Neurology
John R. Adler, MD
Iris C. Gibbs, MD, FACR, FASTRO
Radiation oncologist,
Neuro-oncologist
Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery
Contact us to find out if this trial is right for you.
Contact
ccto-office@stanford.edu
650-498-7061
View on ClinicalTrials.gov
